Amnavero.
← Research directory

Research profile

Retatrutide

Retatrutide activates receptors for GIP, GLP-1, and glucagon. Researchers are evaluating it for chronic weight management.

  • Investigational clinical research
  • Evaluation only
Amnavero Retatrutide research vial concept packaging
Amnavero Retatrutide
Concept packaging

What the research found

A randomized phase 2 study enrolled 338 adults. At 48 weeks, mean weight change in the highest-dose group was −24.2%, compared with −2.1% with placebo.

What remains uncertain

This was a phase 2 result. The drug remains investigational in the United States, and the study did not establish its long-term safety.